Publications by authors named "Mohammad A M Alzahrani"
Background: Aberrant activation of mTORC1 is clearly defined in TSC, causing uncontrolled cell growth. While mTORC1 inhibitors show efficacy to stabilise tumour growth in TSC, they are not fully curative. Disease facets of TSC that are not restored with mTOR inhibitors might involve NF-κB.
View Article and Find Full Text PDFArticle Synopsis
- mTORC1 inhibitors are not a complete cure for tuberous sclerosis complex (TSC), indicating the need for alternative therapeutic approaches.
- Research shows that redox factor-1 (Ref-1) is involved in TSC's disease mechanisms, affecting important transcription factors linked to inflammation, tumor growth, and other processes.
- The Ref-1 inhibitor APX3330 shows promise in reducing tumor cell activity and invasion without affecting mTORC1, suggesting that targeting Ref-1 and its pathways could enhance treatment strategies for TSC.